The Latest News on T1D Medications
Webcast Webcast

The Latest News on T1D Medications


This activity was developed by Med-IQ in collaboration with JDRF and The Leona M. and Harry B. Helmsley Charitable Trust.

Med-IQ     JDRF

Released:
7/30/19
Expires:
7/29/20
PDF:

Maximum Credits:

0.5
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Webcast Webcast
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.
Released:
7/30/19

Expires:
7/29/20

PDF:

Maximum Credits:
0.5
Webcast Webcast
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Released:
7/30/19
Expires:
7/29/20
PDF:


Maximum Credits:
0.5


Overview: Join diabetes experts Anne Peters, MD, and Jay Shubrook, DO, as they talk about the latest advances in treatments for type 1 diabetes (T1D). Explore established and newly available insulin formulations and the possible role of anti-hyperglycemic therapies used in type 2 diabetes for the management of type 1.

CME Information:

Faculty
Anne Peters, MD
Director, USC Clinical Diabetes Program
Professor of Clinical Medicine, Keck School of Medicine of USC
University of Southern California
Los Angeles, CA

Jay H. Shubrook, DO, FACOFP, FAAFP
Professor, Primary Care Department
Director of Clinical Research and Diabetes Services
Touro University California
College of Osteopathic Medicine
Vallejo, CA

Activity Planners
Jaime Symowicz, PhD
Manager, Educational Strategy and Content
Med-IQ
Baltimore, MD
 
Aaron J. Kowalski, PhD
President and CEO
JDRF
New York, NY

Nicole Johnson, DrPH, MPH, MA
National Director
JDRF
New York, NY

Aly Bancroft, MPH
Associate Program Officer
Type 1 Diabetes Program
The Leona M. and Harry B. Helmsley Charitable Trust
New York, NY

Samantha Gordon
CME Specialist
Med-IQ
Baltimore, MD
 
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
Med-IQ
East Lansing, MI
 
Learning Objectives
Upon completion, participants should be able to:

  • Identify the benefits and limitations of new and older insulin formulations
  • Evaluate the advantages and disadvantages of the off-label or investigational use of anti-hyperglycemic medications for individuals with T1D

Target Audience
This activity is intended for primary care clinicians (primary care physicians, pediatricians, nurse practitioners, physician assistants, and nurses), pharmacists, endocrinologists, and certified diabetes educators.
 
Statement of Need
In the United States, approximately 1.25 million individuals have type 1 diabetes (T1D), which includes about 200,000 youth (those younger than 20 years old) and more than 1 million adults (those age 20 and older). Among these individuals, only 17% of youth and 21% of adults are reaching their HbA1c goals. In addition, T1D is a challenging and demanding condition, and many individuals are burdened by insulin treatment plans, hypoglycemia concerns, and psychosocial issues. However, technological advances and new therapies continue to emerge that can help address patients’ challenges and encourage them take a more active role in their care. Because the incidence of T1D is expected to increase to 5 million people by 2050, it is imperative that primary care clinicians stay up-to-date on all aspects of T1D care to improve patient outcomes, such as other measures to assess clinical outcomes; the role of continuous glucose monitoring, insulin pumps, and adjunctive therapies; and the importance of providing support for psychosocial issues.

Collaboration Statement
This activity was developed by Med-IQ in collaboration with JDRF and The Leona M. and Harry B. Helmsley Charitable Trust.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Med-IQ is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This nursing activity has been approved for up to 0.5 contact hour.

ACPEMed-IQ is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.5 contact hour (0.05 CEU) of credit for pharmacists. ACPE #0476-0000-19-005-H01-P. This knowledge-based activity is designed for all pharmacists.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Instructions to Receive Credit
To receive credit, read the introductory CE material, watch the webcast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
 
Initial Release Date: July 30, 2019
Expiration Date: July 29, 2020
Estimated Time to Complete This Activity: 30 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
 
Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
 
Anne Peters, MD
Consulting fees/advisory boards: Abbott Laboratories, Becton, Dickinson and Company, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Lexicon Pharmaceuticals, Inc., Livongo, MannKind Corporation, Merck & Co., Inc., Novo Nordisk, Omada Health, Inc., Optum, Inc., Sanofi-aventis U.S. Inc., Zafgen, Inc.
Fees received for promotional/non-CME activities: Novo Nordisk
Contracted research: AstraZeneca, Dexcom, Inc., MannKind Corporation

Jay H. Shubrook, DO, FACOFP, FAAFP
Consulting fees/advisory boards: Eli Lilly and Company, Novo Nordisk, Intarcia Therapeutics, Inc.

The peer reviewers and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information        
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

System Requirements
Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

ADA Statement
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
 
Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit: www.med-iq.com/privacy-policy.html.

Acknowledgment of Commercial Support
This activity is funded in part by JDRF and The Leona M. and Harry B. Helmsley Charitable Trust and supported by an educational grant from Novo Nordisk, Inc.

Copyright
© 2019 JDRF, Inc.

 

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.

We recently updated our Privacy Notice and Terms of Use.